Kala Reports Positive Results for Phase III Trial of KPI-121 for Post-Cataract Surgery Pain, Inflammation

May 12, 2017: By Jon Swedien

KalaA confirmatory Phase III trial for Kala Pharmaceuticals’ product candidate for post-cataract surgery pain and inflammation produced positive topline results, the Waltham, Massachusetts, company announced May 1.

KPI-121 is a novel nanoparticle formulation of loteprednol etabonate using Kala’s mucus-penetrating particle technology to enhance penetration into tissues of the eye.

The company said it intends to submit a new drug application to the US FDA in late 2017.

In the Phase III multicenter, randomized, double-masked trial of 520 patients, KPI-121 1% was dosed twice daily for two weeks and achieved statistical significance versus placebo for both primary efficacy endpoints and all secondary endpoints, Kala said.

The primary efficacy endpoints were the proportion of patients with complete resolution of anterior chamber cells—a marker of ocular inflammation—in the study eye at day eight, and the proportion of subjects with grade zero pain in the study eye at day eight, Kala said.

Secondary endpoints were complete resolution of anterior chamber flare at day four, complete resolution of pain at day four, and mean change in anterior chamber cells at day four. Each case maintained through day 15 with no need for rescue medication, Kala said.

The positive results followed Kala’s first Phase III trial for KPI-121 1% for post-cataract surgery pain and inflammation that concluded in 2015. In 380 patients, the treatment achieved complete resolution of ocular pain by the eighth day of treatment.

Kala also is studying KPI-121’s effectiveness as a proposed dry eye treatment in a pair of Phase III trials, expected to be completed by the end of 2017.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023